ZYDUS WELLNESS LTD.-$

Zydus Wellness Limited has announced the closure of its trading window for the quarter ending June 30, 2026. The window will be shut from July 1, 2026, and will reopen 48 hours after the declaration of the unaudited financial results for the said quarter. This closure applies to Directors, Designated Persons, and their immediate relatives, restricting them from trading in the company's equity shares. The date for the Board meeting to approve these financial results will be communicated separately.

Zydus Wellness Ltd has announced the incorporation of its step-down wholly owned subsidiary, Zydus Wellness (EU) Limited (ZWEL), in Ireland on June 23, 2026. ZWEL, with a share capital of €100, is established for business expansion in the Vitamins, Minerals and Supplements (VMS) industry. The subsidiary has not yet commenced operations and therefore has no turnover. This move signifies Zydus Wellness's strategic intent to expand its global presence and operations within the VMS sector.

Zydus Wellness Ltd's board approved the appointment of Apurva S. Diwanji as an Additional Director and recommended a final dividend of ₹1.20 per equity share, subject to member approval at the AGM scheduled for August 4, 2026. The record date for determining eligibility for the dividend is set as July 17, 2026. Dividend payment is scheduled on or after August 7, 2026, pending AGM approval.

Zydus Wellness Ltd. reported a 62.1% increase in net sales for Q4 FY26, reaching ₹14,761 million, and a 46.4% YoY growth in annual net sales, totaling ₹39,400 million. EBITDA stood at ₹5,097 million, a 34.2% increase YoY. PAT for FY26 was ₹1,972 million. Sugar Free maintained its market leadership with a 96.1% share, while RiteBite – Max Protein improved to near double-digit margins. Glucon-D maintained its leadership with a 58.9% market share. Everyuth leads in scrubs and peel-off masks, delivering strong double-digit growth. Nycil holds the top position in prickly heat powder with a 33.2% market share.

Zydus Wellness Ltd. announced the appointment of Mr. Apurva S. Diwanji as an Additional Director (Non-Executive & Independent Director) for a 5-year term effective May 18, 2026, subject to member approval. The board also recommended a final dividend of ₹1.20 per equity share, pending approval at the AGM scheduled for August 4, 2026, with a record date of July 17, 2026. Dividend payment is scheduled on or after August 7, 2026, subject to tax deductions.

Zydus Wellness Ltd. announced the approval of audited financial results for the quarter and financial year ended March 31, 2026, following a Board of Directors meeting on May 18, 2026. The board recommended a final dividend of ₹1.20 per equity share, subject to shareholder approval at the Annual General Meeting scheduled for August 4, 2026. The audit reports, with an unmodified opinion from Mukesh M. Shah & Co., Chartered Accountants, are available on the company's website. The trading window will reopen on May 21, 2026.

Zydus Wellness Ltd. announced the approval of audited financial results for the quarter and financial year ended March 31, 2026, following a Board of Directors meeting on May 18, 2026. The board recommended a final dividend of ₹1.20 per equity share (60%) subject to shareholder approval at the AGM scheduled for August 4, 2026. The audit reports, certified by Mukesh M. Shah & Co., Chartered Accountants, expressed an unmodified opinion. The trading window will reopen on May 21, 2026.

Zydus Wellness Ltd. announced the approval of audited financial results for the quarter and year ended March 31, 2026, during a board meeting held on May 18, 2026. The board recommended a final dividend of ₹1.20 per equity share, subject to shareholder approval at the AGM scheduled for August 4, 2026. The audit reports, with an unmodified opinion, were submitted by Mukesh M. Shah & Co., Chartered Accountants. Trading window will re-open on May 21, 2026.

Zydus Wellness Ltd. has scheduled a Board of Directors meeting on May 18, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board will also consider recommending a final dividend for FY26, subject to shareholder approval. The trading window will be closed until May 20, 2026, and will reopen on May 21, 2026.

Zydus Wellness Ltd. has clarified a significant increase in volume of its equity shares across exchanges. The company has made all necessary disclosures of events or information as required by the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The company believes the increase in volume is market-driven and they have no control or knowledge of the reasons for the same.